Interpretation guidelines for antibiotic susceptibility tests of
| Antifungal agent | Organisms | MIC range (μg/mL) | Source | |||
|---|---|---|---|---|---|---|
| S | SDD | I | R | |||
| Amphotericin B | ||||||
| ≤1 | 2 | ≥4 | JCM | |||
| Fluconazole | ||||||
| ≤2 | 4 | ≥8 | CLSI | |||
| ≤32 | ≥64 | CLSI | ||||
| - | - | - | - | |||
| ≤2 | 4 | ≥8 | CLSI | |||
| ≤2 | 4 | ≥8 | CLSI | |||
| Voriconazole | ||||||
| ≤0.12 | 0.25∼0.5 | ≥1 | CLSI | |||
| - | - | - | - | |||
| ≤0.5 | 1 | ≥2 | CLSI | |||
| ≤0.12 | 0.25∼0.5 | ≥1 | CLSI | |||
| ≤0.12 | 0.25∼0.5 | ≥1 | CLSI | |||
| Flucytosine | ||||||
| ≤4 | ≥32 | FDA | ||||
JCM-wild-type MIC distributions and epidemiological cut off values for Amphotericin B, flucytosine, and itraconazole.
Abbreviations: I, intermediate; MIC, minimal inhibitory concentration; R, resistant; S, susceptible; SDD, susceptible dose dependent; JCM, Japan collection of microorganisms; CLSI, clinical and laboratory standards institute; FDA, U.S. Food and Drug Administration.
